Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

PET/MRI Perfusion and CT Perfusion in Solid Tumors (Perfusion)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02314962
Recruitment Status : Terminated (Slow enrolment)
First Posted : December 11, 2014
Last Update Posted : December 16, 2016
Sponsor:
Information provided by (Responsible Party):
University of Zurich

Brief Summary:
Diagnostic comparison between PET/CT and PET/MRI with integrated perfusion measurement in CT and MR. Study aim is to gain knowledge about additional value of CT perfusion and MR perfusion in solid tumors concerning tumor physiology, diagnostic accuracy and possibly prognostic.

Condition or disease
CT Perfusion and MRI Perfusion in Solid Tumors

Layout table for study information
Study Type : Observational
Actual Enrollment : 43 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Diagnostic and Clinical Accuracy of Integrated Magnetic Resonance Imaging and Computed Tomography Perfusion in PET/MRI in Comparison to PET/CT in Solid Tumors
Study Start Date : December 2014
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016



Primary Outcome Measures :
  1. Measurement of blood flow, blood volume and transfer constant (Ktrans) with CT-Perfusion and PET/MR-perfusion in solid tumors. [ Time Frame: 18 months ]

Secondary Outcome Measures :
  1. Correlation of blood flow, blood volume and transfer constant (Ktrans) measured with CT-Perfusion and PET/MR-perfusion with progression free survival in solid tumors. [ Time Frame: 18 months ]

Other Outcome Measures:
  1. Measurement of blood flow (mL/100 mg tissue/min) with CT-Perfusion and PET/MR-perfusion in solid tumors. [ Time Frame: 18 months ]
  2. Measurement of blood volume (mL/100 mg tissue) with CT-Perfusion and PET/MR-perfusion in solid tumors. [ Time Frame: 18 months ]
  3. Measurement of transfer constant with PET/MR-perfusion in solid tumors. [ Time Frame: 18 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with suspected or confirmed solid malignant tumors of the neck, chest or abdomen who have an indication for a PET/CT
Criteria

Inclusion Criteria:

  • indication as stated above
  • written informed consent
  • patients with suspected or confirmed solid malignant tumors of the neck, chest or abdomen who have an indication for a PET/CT

Exclusion Criteria:

  • pregnant or breast feeding women
  • non compliance of the patient to follow the study instructions (e.g. hearing problems, dementia)
  • Inclusion in another clinical trial 30 days prior to inclusion
  • age < 30years
  • contraindication for MRI (cardiac pacemaker, certain metal implants, claustrophobia
  • known allergies to contrast CT or MRI contrast media
  • patients with an glomerular filtration rate of < 60ml/min/1.73m2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02314962


Locations
Layout table for location information
Switzerland
University Hospital Zurich, Diagnostic and Interventional Radiology
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Investigators
Layout table for investigator information
Principal Investigator: Patrick Veit-Haibach, MD University Hospital Zurich, Diagnostic and Interventional Radiology

Layout table for additonal information
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT02314962     History of Changes
Other Study ID Numbers: KEK ZH Nr 20140077
First Posted: December 11, 2014    Key Record Dates
Last Update Posted: December 16, 2016
Last Verified: December 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms